X
Record #64764

Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial

Publisher
Elsevier
Original paper date
Aug 8, 2022
Institution
St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, United Kingdom · Raphael Labs Limited, 6 Derby Street, London, W1J 7AD, United Kingdom · Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, United Kingdom · Danerius, LLC. Sarasota, FL, United States of America · Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, United Kingdom · Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, United Kingdom · Manipal Hospital & Research Center, Mangalore, Karnataka, India · TrialGunva Pvt. LTd, Bengaluru, Karnataka, India · Department of Pulmonology, Atharva Multispeciality Hospital & Research Centre, Lucknow, Uttar Pradesh, India · Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom · Althea Lifesciences, Sahibabad, Uttar Pradesh, India · Queen Mary University of London, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, EC1M 6BQ, United Kingdom
Open access
No
Article type
Clinical Study
Broad categories
(HSC) Medicine - Drug Design(HSC) Medicine - Immunology(HSC) Medicine - Infectious Disease(HSC) Public Health and Safety
Notes from Retraction Watch

see also: https://pubpeer.com/publications/626E12142DA77239E263D482DB56EF

Citation lifecycle

How this paper is being cited

Pre-retraction
11
Same day
0
Post-retraction
1
% post-retraction
8.3%
~4.1 citations/yr before retraction · ~0.7 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse